< Back to latest news & events

HGF Presents

Diagnostic Method Claims at the European Patent Office

September 2025

Video overview:

Why Claims can be Rejected

  • Diagnostic method claims can be refused if they include all four steps of the diagnostic process involving interaction with the human or animal body:
    1. Interaction with the human or animal body.
    2. Comparison against standard values.
    3. Finding significant deviations.
    4. Attribution of deviation to a clinical situation.
  • If any step is missing or no interaction with the body is claimed, the exclusion does not apply.

Drafting Tips to Overcome Rejection

  • Consider drafting claims without the final diagnosis step, e.g., focus on a new method of data collection.
  • Avoid steps requiring interaction with the body if possible; instead, define methods as performed in vitro or ex vivo.
  • If all four steps are claimed and interaction occurs, convert the claim into a first or second medical use claim, using a compound or composition. (Note: Diagnostic medical devices cannot be protected this way.)

Practical Reminders

  • The EPO applies a strict test for added subject matter — draft carefully to avoid post-filing issues.
  • Ensure the claims clearly separate the technical method from the excluded diagnostic steps if possible.
  • Remember that the EPO applies a strict assessment of added subject matter.

Latest updates

The concept of ‘overall impression’ in UK and EU Registered Design Law

 

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
Event - 7th January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article